Combating Combination of Hypertension and Diabetes in Different Rat Models

Rat experimental models are used extensively for studying physiological mechanisms and treatments of hypertension and diabetes co-existence. Each one of these conditions is a major risk factor for cardiovascular disease (CVD), and the combination of the two conditions is a potent enhancer of CVD. Fi...

Full description

Bibliographic Details
Main Authors: Talma Rosenthal, Firas Younis, Ariela Alter
Format: Article
Language:English
Published: MDPI AG 2010-03-01
Series:Pharmaceuticals
Subjects:
Online Access:http://www.mdpi.com/1424-8247/3/4/916/
_version_ 1818228439222583296
author Talma Rosenthal
Firas Younis
Ariela Alter
author_facet Talma Rosenthal
Firas Younis
Ariela Alter
author_sort Talma Rosenthal
collection DOAJ
description Rat experimental models are used extensively for studying physiological mechanisms and treatments of hypertension and diabetes co-existence. Each one of these conditions is a major risk factor for cardiovascular disease (CVD), and the combination of the two conditions is a potent enhancer of CVD. Five major animal models that advanced our understanding of the mechanisms and therapeutic approaches in humans are discussed in this review: Zucker, Goto-Kakizaki, SHROB, SHR/NDmcr-cp and Cohen Rosenthal diabetic hypertensive (CRDH) rats. The use of various drugs, such as angiotensin-converting enzyme (ACE) inhibitors (ACEIs), various angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs), to combat the effects of concomitant pathologies on the combination of diabetes and hypertension, as well as the non-pharmacological approach are reviewed in detail for each rat model. Results from experiments on these models indicate that classical factors contributing to the pathology of hypertension and diabetes combination—Including hypertension, hyperglycemia, hyperinsulinemia and hyperlipidemia—can now be treated, although these treatments do not completely prevent renal complications. Animal studies have focused on several mechanisms involved in hypertension/diabetes that remain to be translated into clinical medicine, including hypoxia, oxidative stress, and advanced glycation. Several target molecules have been identified that need to be incorporated into a treatment modality. The challenge continues to be the identification and interpretation of the clinical evidence from the animal models and their application to human treatment.
first_indexed 2024-12-12T10:02:43Z
format Article
id doaj.art-06fe031a25b84d30865d5e34cc1ec3e4
institution Directory Open Access Journal
issn 1424-8247
language English
last_indexed 2024-12-12T10:02:43Z
publishDate 2010-03-01
publisher MDPI AG
record_format Article
series Pharmaceuticals
spelling doaj.art-06fe031a25b84d30865d5e34cc1ec3e42022-12-22T00:27:58ZengMDPI AGPharmaceuticals1424-82472010-03-013491693910.3390/ph3040916Combating Combination of Hypertension and Diabetes in Different Rat ModelsTalma RosenthalFiras YounisAriela AlterRat experimental models are used extensively for studying physiological mechanisms and treatments of hypertension and diabetes co-existence. Each one of these conditions is a major risk factor for cardiovascular disease (CVD), and the combination of the two conditions is a potent enhancer of CVD. Five major animal models that advanced our understanding of the mechanisms and therapeutic approaches in humans are discussed in this review: Zucker, Goto-Kakizaki, SHROB, SHR/NDmcr-cp and Cohen Rosenthal diabetic hypertensive (CRDH) rats. The use of various drugs, such as angiotensin-converting enzyme (ACE) inhibitors (ACEIs), various angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs), to combat the effects of concomitant pathologies on the combination of diabetes and hypertension, as well as the non-pharmacological approach are reviewed in detail for each rat model. Results from experiments on these models indicate that classical factors contributing to the pathology of hypertension and diabetes combination—Including hypertension, hyperglycemia, hyperinsulinemia and hyperlipidemia—can now be treated, although these treatments do not completely prevent renal complications. Animal studies have focused on several mechanisms involved in hypertension/diabetes that remain to be translated into clinical medicine, including hypoxia, oxidative stress, and advanced glycation. Several target molecules have been identified that need to be incorporated into a treatment modality. The challenge continues to be the identification and interpretation of the clinical evidence from the animal models and their application to human treatment.http://www.mdpi.com/1424-8247/3/4/916/hypertensive-diabetic animal models – treatmentZucker ratsGoto-Kakizaki ratsSHROB ratsSHR/NDmcr-cp ratsCohen Rosenthal diabetic hypertensive rats
spellingShingle Talma Rosenthal
Firas Younis
Ariela Alter
Combating Combination of Hypertension and Diabetes in Different Rat Models
Pharmaceuticals
hypertensive-diabetic animal models – treatment
Zucker rats
Goto-Kakizaki rats
SHROB rats
SHR/NDmcr-cp rats
Cohen Rosenthal diabetic hypertensive rats
title Combating Combination of Hypertension and Diabetes in Different Rat Models
title_full Combating Combination of Hypertension and Diabetes in Different Rat Models
title_fullStr Combating Combination of Hypertension and Diabetes in Different Rat Models
title_full_unstemmed Combating Combination of Hypertension and Diabetes in Different Rat Models
title_short Combating Combination of Hypertension and Diabetes in Different Rat Models
title_sort combating combination of hypertension and diabetes in different rat models
topic hypertensive-diabetic animal models – treatment
Zucker rats
Goto-Kakizaki rats
SHROB rats
SHR/NDmcr-cp rats
Cohen Rosenthal diabetic hypertensive rats
url http://www.mdpi.com/1424-8247/3/4/916/
work_keys_str_mv AT talmarosenthal combatingcombinationofhypertensionanddiabetesindifferentratmodels
AT firasyounis combatingcombinationofhypertensionanddiabetesindifferentratmodels
AT arielaalter combatingcombinationofhypertensionanddiabetesindifferentratmodels